Tvkan
@Tvkan@feddit.de
- Comment on Recycling 4-year-old 737 memes (Part 1) 11 months ago:
But you compared it to other planes, not to cars. Please leave the goal posts were they are.
- Comment on Why do new sites embed tweets? 1 year ago:
If you’re a large online news outlet doing this repeatedly: Probably sue you.
- Comment on Gamers enraged at Ubisoft for injecting ads into the middle of video games 1 year ago:
-
It’s page one, so I don’t think this is a selected subset.
-
This is just the people playing right now, and only people playing on steam. This doesn’t show all of the people who bought the game or are playing on console.
-
Obviously none of the gaming boycotts have worked, and we’re both putting way too much thought into one image.
-
- Comment on Gamers enraged at Ubisoft for injecting ads into the middle of video games 1 year ago:
- Comment on Nothing Phone builds a blue bubble iMessage bridge while Google and Apple fight over RCS 1 year ago:
Probably when it was beaten in both features and cost by the alternatives.
- Comment on Ultra-white ceramic cools buildings with record-high 99.6% reflectivity 1 year ago:
In other news, snow blindness is on the rise in suburbia.
- Comment on Tumblr is reportedly on life support as its latest owner reassigns staff 1 year ago:
It would solve so many problems over there, honestly.
Which ones?
- Comment on Push It Somewhere Else 1 year ago:
May a capella sink with it.
- Comment on Push It Somewhere Else 1 year ago:
Sssshhh. Let it sink.
- Comment on Pfizer says it will price Covid treatment Paxlovid at nearly $1,400 for a five-day course, which researchers estimate only costs Pfizer $13 to produce. That's a 10,000%+ markup. Shameful. 1 year ago:
Pfizer conducts research in various areas, including MS therapy. That costs a lot of money.
Like when Roche refused to study Rituximab in multiple sclerosis, which has been succesfully used as an off-label medication for more than a decade, and then released Ocrelizumab for MS, a totally different and not at all virtually identical drug for ten times the price?
Pfizer has a profit margin of ~30%, and that’s after lobbying and advertising and the billions of fines they had to pay for illegal advertising and kickbacks. Unsurprisingly, extractable profit is a really bad proxy for people’s health.
But I can’t complain anyway, here in Germany you can get Paxlovid free of charge because it’s prescribed by a doctor.
While I usually think the “free at point of service”-argument isn’t necessary, it’s very relevant here. You’re still paying for it, and all the other drugs that have come out over the last few years that are much, much more expensive than the therapies they replace.
Take a look at GLP-1-agonists (Wegovy, Ozempic, …) which will come to replace/combine with oral antidiabetics like metformine and have now also been approved for obesity without diabetes.
Metformine is basically free a 10ct/pill, i.e. ~3€/patient/month. GLP-1-agonists cost about 250 - 1000€/patient/month. More than half of the German population is overweight, and more than one in eight suffer from type 2 diabetes - with both figures on the rise.
This trend of massive price increases with every new generation of drugs is extremely dangerous healthcare systems themselves, especially public ones, and of course the patients themselves in the end. Every price hike sets a new baseline, and we need to be very, very careful about compounding effects.
- Comment on Well, it was nice while it lasted? 1 year ago:
Nice.
- Comment on Well, it was nice while it lasted? 1 year ago:
A25
- Comment on Goodbye Youtube and thanks for all the fish 1 year ago:
This calls for Bloonface’s rebuttal.
- Comment on Are metric measurements like decameters and hectometers ever used? 1 year ago:
Ah jeez, thank you. Fixed it.
- Comment on Are metric measurements like decameters and hectometers ever used? 1 year ago:
No, you’re thinking of a kilogram. A liter and 10dm³ are identical.
- Comment on Do they know one second is slow? 1 year ago:
complains about losing one second
literally has an “sign up for my newsletter!”-overlay that appears in front of the article, while you’re reading the article